STL Volume 30 Number 5

Health Canada approved selumetinib in 2022 for treating inoperable plexiform neurofibromas in children with neurofibromatosis type 1. Clinical trials showed 74% of patients experienced significant tumor shrinkage, with improvements in pain and quality of life. The oral MEK inhibitor offers the first targeted therapy for these historically difficult-to-treat nerve tumors.

Upadacitinib shows sustained long-term efficacy and safety for moderate-to-severe atopic dermatitis in 76-week studies. The oral JAK inhibitor maintains 80%+ EASI-75 response rates with manageable side effects, outperforming dupilumab in head-to-head trials while offering faster symptom relief for chronic eczema patients.

Update on Delgocitinib cream (Anzupgo®), Recombinant zoster vaccine (Shingrix®), Sebetralstat tablets (Ekterly®), and Lifileucel for IV infusion (Amtagvi®).